TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04487925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A single Gonadotropin-Releasing Hormone (GnRH) antagonist corifollitropin alfa (CFA) stimulation
Description: CFA will be administered in combination with Follitropin beta.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Up to three modified natural cycles with Follitropin beta.
Description: Follitropin beta in a low dose will be given.
Study: NCT05363111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Actinium Ac 225-DOTA-Daratumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Indium In 111-DOTA-Daratumumab
Description: Given IV
Study: NCT06191172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminiscence Therapy
Description: Old objects and pictures of old objects that facilitate remembering about weekly topics will be taken to the institution by the researcher, and individuals within the scope of the research will be asked for their own photographs, if any.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Montessori application
Description: Drill toy Matching puzzle Chickpeas, rice sorting Lock, zipper Counting beans Making a tie Taking and pouring food with a scoop

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental Layout
Description: Dining place Music Lighting Heat

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Application of contrast ergonomic special equipment
Description: White tablecloth Beveled red blue and yellow blue plate Ergonomic yellow and red fork, spoon and cup
Study: NCT05226312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Warm Compress
Description: The warm application will be made by the researcher for 15 minutes three times a day according to the local warm application process steps.
Study: NCT05238337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-PBI-200
Description: \[14C\]-radio-labeled-PBI-200
Study: NCT06478303

Intervention type: OTHER
Intervention: Motor imagery
Description: Participants were asked to imagine arm or foot movements.

Intervention type: OTHER
Intervention: Motor imagery
Description: Participants were asked to imagine arm or foot movements.

Intervention type: OTHER
Intervention: Motor imagery
Description: Participants were asked to imagine arm or foot movements.

Intervention type: OTHER
Intervention: Motor imagery
Description: Participants were asked to imagine arm or foot movements.

Intervention type: OTHER
Intervention: Motor imagery
Description: Participants were asked to imagine arm or foot movements.

Intervention type: OTHER
Intervention: Action reading
Description: Participants were asked to read sentences involving arm or foot movements

Intervention type: OTHER
Intervention: Action reading
Description: Participants were asked to read sentences involving arm or foot movements

Intervention type: OTHER
Intervention: Action reading
Description: Participants were asked to read sentences involving arm or foot movements

Intervention type: OTHER
Intervention: Action reading
Description: Participants were asked to read sentences involving arm or foot movements

Intervention type: OTHER
Intervention: Action reading
Description: Participants were asked to read sentences involving arm or foot movements

Intervention type: OTHER
Intervention: Motor localizer
Description: Participants were asked to perform arm or foot movements
Study: NCT04951700

Intervention type: OTHER
Intervention: Other
Description: This is not an intervention study

Intervention type: OTHER
Intervention: Other
Description: This is not an intervention study
Study: NCT05009329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: JAB-21822 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: JAB-21822 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: JAB-21822 will be administered orally
Study: NCT05029739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A PAD-specific smartphone application (e-intervention) developed for patients with Peripheral Artery Disease
Description: See description of the e-intervention group as above.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A PAD-specific smartphone application (e-intervention) developed for patients with Peripheral Artery Disease
Description: See description of the e-intervention group as above.
Study: NCT06526091

Intervention type: OTHER
Intervention: Cerebral NIRS monitoring at delivery
Description: Application of cerebral NIRS monitoring immediately after delivery and during optimum cord management
Study: NCT05214092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech sound stimulation
Description: Participants will listen to repetitive speech sound stimuli, presented through headphones, which will induce a neural response (frequency-following response) to be measured via electroencephalography and pupillometry
Study: NCT04762134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Hyclate
Description: STI PrEP arm: doxycycline capsules 100mg orally daily for 12 months STI PEP arm: doxycycline 200mg orally once within 24-72 hours following each sexual encounter deemed at risk (i.e. condomless anal or oral sex), to a maximum of six pills (i.e. 600 mg total) per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Hyclate
Description: STI PrEP arm: doxycycline capsules 100mg orally daily for 12 months STI PEP arm: doxycycline 200mg orally once within 24-72 hours following each sexual encounter deemed at risk (i.e. condomless anal or oral sex), to a maximum of six pills (i.e. 600 mg total) per week
Study: NCT04486846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eVisit
Description: electronic surveillance program in lieu of in-person clinic visit
Study: NCT04946916

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sample taken
Description: Comparaison of Neurofilament light chain serum concentration between the arms

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sample taken
Description: Comparaison of Neurofilament light chain serum concentration between the arms

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sample taken
Description: Comparaison of Neurofilament light chain serum concentration between the arms

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sample taken
Description: Comparaison of Neurofilament light chain serum concentration between the arms
Study: NCT06050499

Intervention type: DEVICE
Intervention: Microdialysis catheter + biosensor
Description: Microdialysis catheter from linton instrumetal 63 MD Catheter
Study: NCT05400928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation
Description: pulmonary vein isolation will be performed with ring-shaped pulsed field ablation catheter directed by integrated three-dimensional mapping system
Study: NCT06114758

Intervention type: DRUG
Intervention: Cytotec 200Mcg Tablet
Description: the admistiration of 400 Mcg rectal cytotec while starting the surgery, just before the patient is covered

Intervention type: DRUG
Intervention: Transamine
Description: 1 gram intravenous slow infusion intraoperatively as we start the laparatomy
Study: NCT05261984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise
Description: Knee extensions in flywheel inertia machine in four sets of 10 repetitions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Knee extensions in flywheel inertia machine in four sets of 10 repetitions.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral protein supplementation
Description: 24 grams of hydrolyzed whey protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral protein supplementation
Description: 24 grams of hydrolyzed whey protein.
Study: NCT06303063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SINOMED IAS Stent System
Description: Stent-assisted coiling (SAC) of intracranial aneurysms paved the way for endovascular coiling of wide-neck aneurysms, improving rates of aneurysm obliteration and recurrence.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuroform Atlas Stent System
Description: Stent-assisted coiling (SAC) of intracranial aneurysms paved the way for endovascular coiling of wide-neck aneurysms, improving rates of aneurysm obliteration and recurrence.
Study: NCT05179772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine (2.5 mg to 20 mg)
Study: NCT05067296

Intervention type: OTHER
Intervention: By TVS
Description: Uses of TVS to diagnosis of Cesarean section niche in patients with abnormal uterine bleeding
Study: NCT05789901

Intervention type: OTHER
Group type: OTHER
Intervention: MARVIN
Description: Chatbot on Meta (Facebook) Messenger for HIV Patients

Intervention type: OTHER
Group type: OTHER
Intervention: MARVIN-Pharma
Description: Chatbot on Meta (Facebook) Messenger for community pharmacists

Intervention type: OTHER
Group type: OTHER
Intervention: MARVINA
Description: Chatbot on Meta (Facebook) Messenger for breast cancer patients
Study: NCT06220578

Intervention type: DEVICE
Intervention: Oculus pentacam HR
Description: Examination of corneal parameters by pentacam
Study: NCT04093388

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Self-PAP
Description: A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Traditional Pap smear
Description: A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
Study: NCT06353347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801
Description: HTD1801 1000 mg administered orally BID as four capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally BID as four capsules
Study: NCT04988256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Patients randomized to cyclosporine will be treated as mentioned under Arm/Group Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and Prednisone
Description: All patients randomized to steroids will initially be treated with IV methylprednisolone and eventually started on an oral prednisone taper.
Study: NCT04107272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real repetitive transcranial magnetic stimulation
Description: The real rTMS will be delivered over M1 (hand representation) of dual hemispheres with 10 trains of 10 Hz pulses for 10 seconds, with a total of 1,000 pulses per hemisphere. The real rTMS intensity will be set as 80% resting motor threshold and the interval between each train of pulses will be set as 50 seconds. The real rTMS will be delivered as daily session for five consecutive days, followed by two fortnightly maintenance sessions during the follow-up period after the completion of five daily sessions. The real rTMS will be delivered by designated physical therapists using figure-of-8 shaped coil.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: The sham rTMS of this study will be delivered with the same active coil angled 90-degree way from the scalp. The intensity of sham rTMS will be set at lowest stimulator output that can generate similar noise to the real rTMS. The sham rTMS will be delivered in the same manner and duration with real rTMS.
Study: NCT05808322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b
Description: A maximum of 3 doses of ropeginterferon alfa-2b will be given biweekly during the whole study period. A single dose of 250 μg ropeginterferon alfa-2b will be subcutaneous administrated at Day 1 visit. SARS-CoV-2 antigen test will be conducted at D15 and D29 visits. For patients who still have positive result in SARS-CoV-2 antigen test at Day 15 visit, the second dose of ropeginterferon alfa-2b at 350 μg will be subsequently administered at Day 15 visit. For patients who still have positive result in SARS-CoV-2 antigen test at Day 29 visit, the third dose of ropeginterferon alfa-2b at 500 μg will be administered at Day 29 visit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SOC
Description: SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
Study: NCT05999214

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTc-H7ND SPECT/CT imaging performed
Description: 99mTc-H7ND SPECT/CT imaging positive (+) was defined as the presence of at least one measurable lesion and the uptake of the lesion was greater than that of normal liver in the experimental group, and patients were divided into SD+ and SD-. According to the guidelines and routine clinical practice, SD- patients were treated with the original regimen or maintenance treatment, and SD+ patients were divided into continuation of the original regimen or second-line treatment according to the MDT discussion results.
Study: NCT05608876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigilanol Tiglate
Description: Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
Study: NCT06416514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized intervention
Description: Personalized intervention means implementing multi-component non-pharmacological interventions based on different health profiles，such as art therapy, exercise therapy, cognitive therapy and other monotherapies. Usual care means care as routine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized intervention
Description: Personalized intervention means implementing multi-component non-pharmacological interventions based on different health profiles，such as art therapy, exercise therapy, cognitive therapy and other monotherapies. Usual care means care as routine.
Study: NCT05789901

Intervention type: OTHER
Group type: OTHER
Intervention: MARVIN-CHAMP
Description: CHatbot to Assist the Management of Pediatric patients with infectious conditions (CHAMP)
Study: NCT05171816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: 300 mg (2 x 150 milligrams (mg) tablets) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: 1000 milligrams (mg) once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: abiraterone acetate
Description: 1000 milligrams (mg) once daily
Study: NCT03077399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCALA
Description: All items of SCALA are applied

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCALA
Description: All items of SCALA are applied
Study: NCT05049109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Telehealth After Stroke Care
Description: • 3 week and 8 week follow up visits with pharmacy through telehealth~Patients will provide home blood pressure monitoring kits at discharge for the first three months. The telemonitor that can send blood pressure readings, wirelessly or through telephone, to a secure server where study staff can look at the readings. Any blood pressure readings that are not within normal range will trigger an alert to be sent to study staff who will then follow up with the patient. A trained staff member will show the patient how to use the blood pressure monitor. Patients will be asked to take blood pressure at least 3 days per week and transmit the readings to study staff.~Patients will also be asked to wear an activity monitor starting at 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual post-stroke follow-up care
Description: * 1-2 weeks follow up visit with primary care.~* 4-6 week and 12 week follow up visit with stroke practitioner~* At the end of the study, patients will be asked questions regarding their experience with the telehealth visits, health, medication taking and quality of life

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual post-stroke follow-up care
Description: * 1-2 weeks follow up visit with primary care.~* 4-6 week and 12 week follow up visit with stroke practitioner~* At the end of the study, patients will be asked questions regarding their experience with the telehealth visits, health, medication taking and quality of life
Study: NCT04814056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib Dimaleate
Description: Afatinib is the second-generation TKI drug, which can irreversibly bind to receptors of erbB family. Afatinib will be administered orally at a dose of 40 mg per time, Q.D. If a patient cannot tolerate a dose of 40mg due to adverse reactions, when the adverse reactions restore to level 1 (CTCAE 5.0) or below, the dosage could be adjusted to 30mg per day, Q.D.
Study: NCT06121024

Intervention type: PROCEDURE
Intervention: Interventional Bronchoscopy
Description: Bronchoscopy offers vital information when evaluating patients suffering from tracheal stenosis. It enables direct visualisation which identifies the lesion, determines its location and extent of airway involvement, highlights vascularity and fragility, allows for tissue diagnosis and enables the operator to assess the extent of mucosal infiltration and airway compression caused by the tumour. The technique facilitates assessment of stenosis diameter for suitable stent selection. In addition to enabling diagnostic bronchoscopy, rigid bronchoscopy offers therapeutic options such as dilatation, cryotherapy and stenting for tracheal stenosis patients. Our clinical setting employs rigid bronchoscopy for interventional procedures with both diagnostic and therapeutic aspects.

Intervention type: PROCEDURE
Intervention: Interventional Bronchoscopy
Description: Bronchoscopy offers vital information when evaluating patients suffering from tracheal stenosis. It enables direct visualisation which identifies the lesion, determines its location and extent of airway involvement, highlights vascularity and fragility, allows for tissue diagnosis and enables the operator to assess the extent of mucosal infiltration and airway compression caused by the tumour. The technique facilitates assessment of stenosis diameter for suitable stent selection. In addition to enabling diagnostic bronchoscopy, rigid bronchoscopy offers therapeutic options such as dilatation, cryotherapy and stenting for tracheal stenosis patients. Our clinical setting employs rigid bronchoscopy for interventional procedures with both diagnostic and therapeutic aspects.
Study: NCT04421248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: In ADHD participants only: blinded, randomized, placebo-controlled single dose, crossover on separate days separated by at least one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In ADHD participants only: blinded, randomized, placebo-controlled, single dose, crossover on separate days separated by at least one week.
Study: NCT05949632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: Administered as specified in the treatment arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: Administered as specified in the treatment arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Administered as specified in the treatment arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Administered as specified in the treatment arm description
Study: NCT05945173

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evaporation time for 5 seconds
Description: Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 5 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evaporation time for 5 seconds
Description: Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 5 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Evaporation time for 25 seconds
Description: Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 25 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Evaporation time for 25 seconds
Description: Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 25 seconds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alcohol/water-based universal adhesive
Description: Composite resin restorations of non-carious cervical lesions will be performed with an alcohol/water-based universal adhesive (Scotchbond Universal Plus; 3M).
Study: NCT06297707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic high intensity resistive training
Description: The experimental group participants will involve in aquatic high intensity resistive training sessions. The participants in the intervention group will receive 1 h of supervised lower limb aquatic resistance training three times a week for 12 weeks, for a total of 36 training sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: The control group will maintain usual care and will be asked to continue their usual leisure time activities. They will be offered the possibility of participating in two sessions consisting of 1 h of light stretching and relaxation during the 3-month intervention period.
Study: NCT05164926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perineal massage with St. John's Wort oil
Description: perineal massage with St. John's Wort oil during labor
Study: NCT05026203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Ketamine hydrochloride 0.5 mg/kg intravenous administer in 40 minutes per day for 3 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam
Study: NCT05171712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement
Description: Transcatheter Aortic Valve Replacement for the treatment of patients with severe aortic stenosis